FY2025 EPS Estimates for Hologic Raised by Leerink Partnrs

Hologic, Inc. (NASDAQ:HOLX - Free Report) - Stock analysts at Leerink Partnrs raised their FY2025 EPS estimates for shares of Hologic in a research report issued on Wednesday, December 11th. Leerink Partnrs analyst P. Souda now expects that the medical equipment provider will post earnings per share of $4.31 for the year, up from their previous estimate of $4.27. The consensus estimate for Hologic's current full-year earnings is $4.28 per share. Leerink Partnrs also issued estimates for Hologic's Q4 2025 earnings at $1.14 EPS, Q1 2026 earnings at $1.12 EPS, Q2 2026 earnings at $1.16 EPS, Q3 2026 earnings at $1.20 EPS, Q4 2026 earnings at $1.21 EPS and FY2026 earnings at $4.69 EPS.

Several other brokerages have also issued reports on HOLX. Mizuho decreased their price target on shares of Hologic from $90.00 to $87.00 and set an "outperform" rating for the company in a research note on Tuesday, November 5th. Needham & Company LLC restated a "buy" rating and issued a $90.00 target price on shares of Hologic in a research note on Tuesday, December 10th. StockNews.com upgraded Hologic from a "hold" rating to a "buy" rating in a research note on Thursday, November 14th. JPMorgan Chase & Co. boosted their price objective on Hologic from $92.00 to $94.00 and gave the company an "overweight" rating in a research note on Tuesday, November 5th. Finally, Jefferies Financial Group began coverage on shares of Hologic in a report on Tuesday, December 10th. They set a "hold" rating and a $85.00 price objective on the stock. Six research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $89.50.

Hologic Stock Performance

Shares of NASDAQ:HOLX traded down $1.21 during midday trading on Monday, reaching $72.44. The company had a trading volume of 2,551,828 shares, compared to its average volume of 1,630,649. The stock has a market cap of $16.44 billion, a P/E ratio of 21.75, a P/E/G ratio of 2.38 and a beta of 0.96. The company's 50 day moving average price is $79.17 and its 200 day moving average price is $78.64. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. Hologic has a 52-week low of $70.24 and a 52-week high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting analysts' consensus estimates of $1.01. The business had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. Hologic's quarterly revenue was up 4.5% compared to the same quarter last year. During the same period last year, the company posted $0.89 earnings per share.

Insider Buying and Selling

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.75% of the stock is owned by company insiders.

Hedge Funds Weigh In On Hologic

Institutional investors have recently made changes to their positions in the stock. Oddo BHF Asset Management Sas purchased a new stake in Hologic during the third quarter valued at about $1,110,000. Franklin Resources Inc. raised its holdings in shares of Hologic by 171.7% during the 3rd quarter. Franklin Resources Inc. now owns 278,295 shares of the medical equipment provider's stock valued at $22,714,000 after buying an additional 175,855 shares in the last quarter. Tidal Investments LLC lifted its position in Hologic by 60.1% in the 3rd quarter. Tidal Investments LLC now owns 15,351 shares of the medical equipment provider's stock worth $1,250,000 after buying an additional 5,764 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Hologic in the 3rd quarter worth approximately $93,000. Finally, Sanctuary Advisors LLC boosted its stake in Hologic by 4.2% in the third quarter. Sanctuary Advisors LLC now owns 16,613 shares of the medical equipment provider's stock worth $1,312,000 after buying an additional 667 shares in the last quarter. Institutional investors own 94.73% of the company's stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.